All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “BITES Bispecifics and Checkpoints” took place.
One of the posters on display (3631 / 4) was titled “Delivery of a CD20 transferrin receptor VNAR bispecific antibody to the brain for CNS lymphoma” by Frank S. Walsh from Ossianix, Philadelphia, PA, and colleagues.
Currently, the challenge facing the development of biologic therapies for CNS-related cancers is getting the agent to cross the blood brain barrier.
This group used in vitro and in vivo phage display technology; they identified a panel of cross species (rodent, primate, and human) binders to the Transferrin Receptor 1 (TfR1) from synthetic libraries of shark Variable Antigen Receptors (VNARs).
The poster concluded by stating that these bispecific formats will be investigated further for brain penetration in non-human primates and in CNS Lymphoma rodent models.
If these results are successfully replicated in larger animals, the delivery of the bispecific CD20/TfR1 antibody would present as a safer and more effective substitute to intrathecal delivery of CD20 antibody and could have wide range of uses to treat and manage B-cell driven brain cancers.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?